California lawmakers are advancing bills on customer-service chatbots, rare-disease drug approvals, and subpoenas for protected health care records. For physicians, the bills point to a larger trend: state policy now reaches into the daily mechanics of clinical practice.
The most direct clinical measure is AB 1887, a rare-disease treatment access bill. The bill would require health plans and insurers to complete prior authorization or other utilization review within 30 days for certain FDA-approved rare-disease drugs when a specialist with expertise in the condition prescribes the drug and determines it is medically necessary. The bill would also prohibit step therapy for those drugs unless a biosimilar, interchangeable biologic, or generic version is available.
For physicians, the practical significance is clear. Rare-disease patients often depend on specialist-directed therapies that may be expensive, time-sensitive, and difficult to substitute. AB 1887 would not eliminate prior authorization, but it would establish a defined review timeline for qualifying drugs and push payers to make decisions faster. Specialists would likely need to document the diagnosis, medical necessity, FDA-approved indication, relevant expertise, and absence of a suitable alternative.
A second bill, AB 1930, moves the physician workflow issue into legal and privacy territory. The bill would restrict California entities from complying with certain investigations, subpoenas, or summonses seeking information about abortion or gender-affirming health care services unless a court orders compliance or the entity meets specified statutory conditions. Those conditions include notice to the California Attorney General and reasonable efforts to notify affected individuals before releasing responsive information, subject to court orders and federal-law exceptions.
Physicians and medical groups should not manage these requests informally. Any subpoena or legal demand involving protected reproductive or gender-affirming care should move through legal, privacy, and compliance channels. The bill reminds medical practices that sensitive care records pose more than a documentation issue. They also create obligations related to compliance, privacy, and patient trust.
The third bill, AB 1609, addresses customer-service chatbots. It would prohibit large private businesses from presenting a customer-service chatbot as human and require disclosure when a reasonable person could mistakenly believe the chatbot is human. It would also require large businesses to provide a customer-service feature that lets consumers contact a human agent for at least 10 hours per day during regular business hours, with a good-faith effort to connect a customer within 15 minutes.
The physician angle is more indirect because the bill includes a broad exemption for many nonprofit general acute-care hospital communications related to health-care operations, including patient care, scheduling, referrals, prior authorization, billing, and insurance. Still, AB 1609 raises a larger AI-governance question for health care: when patients interact with automated systems, do they know when they are dealing with AI, and can they reach a human when the issue affects care?
AB 1887 has the most immediate clinical relevance because it targets treatment delays for rare diseases. AB 1930 raises the most sensitive legal and privacy questions because it concerns protected health care records. AB 1609 sends the AI signal, but its hospital exemption means health systems may need to set their own standards for chatbot disclosure, human escalation, and patient safety.